|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parums DV: Current status of targeted
therapy in non-small cell lung cancer. Drugs Today (Barc).
50:503–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Fukuoka M and Baselga J:
Gefitinib - a novel targeted approach to treating cancer. Nat Rev
Cancer. 4:956–965. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A,
Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, et al: Impact
of specific epidermal growth factor receptor (EGFR) mutations and
clinical characteristics on outcomes after treatment with EGFR
tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung
cancer: A meta-analysis. J Clin Oncol. 33:1958–1965. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miller VA, Kris MG, Shah N, Patel J,
Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, et al:
Bronchioloalveolar pathologic subtype and smoking history predict
sensitivity to gefitinib in advanced non-small-cell lung cancer. J
Clin Oncol. 22:1103–1109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maruyama R, Nishiwaki Y, Tamura T,
Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F,
Eguchi K, et al: Phase III study, V-15-32, of gefitinib versus
docetaxel in previously treated Japanese patients with
non-small-cell lung cancer. J Clin Oncol. 26:4244–4252. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee CK, Brown C, Gralla RJ, Hirsh V,
Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu T, Zaatar A, et al:
Impact of EGFR inhibitor in non-small cell lung cancer on
progression-free and overall survival: A meta-analysis. J Natl
Cancer Inst. 105:595–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kris MG: How today's developments in the
treatment of non-small cell lung cancer will change tomorrow's
standards of care. Oncologist. 10 Suppl 2:23–29. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirsch FR and Bunn PA Jr.: EGFR testing in
lung cancer is ready for prime time. Lancet Oncol. 10:432–433.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kohno T, Nakaoku T, Tsuta K, Tsuchihara K,
Matsumoto S, Yoh K and Goto K: Beyond ALK-RET ROS1 and other
oncogene fusions in lung cancer. Transl Lung Cancer Res. 4:156–164.
2015.PubMed/NCBI
|
|
15
|
Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H,
Ren-Heidenreich L, Shi B, Ren H, Chu X, et al: Coexistence of EGFR
with KRAS or BRAF or PIK 3CA somatic mutations in lung cancer: A
comprehensive mutation profiling from 5125 Chinese cohorts. Br J
Cancer. 110:2812–2820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi
H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, et
al: EGFR exon 18 mutations in lung cancer: Molecular predictors of
augmented sensitivity to afatinib or neratinib as compared with
first- or third-generation TKIs. Clin Cancer Res. 21:5305–5313.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han B, Tjulandin S, Hagiwara K, Normanno
N, Wulandari L, Konstantinovich L Konstantin, Hudoyo A, Ratcliffe
M, McCormack R and Reck M: Determining the prevalence of EGFR
mutations in Asian and Russian patients (PTS) with advanced
non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and
non-ADC histology: Ignite study. Ann Oncol. 26 Suppl 1:i29–i30.
2015. View Article : Google Scholar
|
|
18
|
Beau-Faller M, Prim N, Ruppert AM,
Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet
JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in
non-small-cell lung cancer on 10 117 patients: A multicentre
observational study by the French ERMETIC-IFCT network. Ann Oncol.
25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ,
Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, et al: Identification
of enriched driver gene alterations in subgroups of non-small cell
lung cancer patients based on histology and smoking status. PLoS
One. 7:e401092012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gahr S, Stoehr R, Geissinger E, Ficker JH,
Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C,
Rieker RJ, et al: EGFR mutational status in a large series of
Caucasian European NSCLC patients: Data from daily practice. Br J
Cancer. 109:1821–1828. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Skov BG, Høgdall E, Clementsen P, Krasnik
M, Larsen KR, Sørensen JB, Skov T and Mellemgaard A: The prevalence
of EGFR mutations in non-small cell lung cancer in an unselected
Caucasian population. APMIS. 123:108–115. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han SW, Kim TY, Hwang PG, Jeong S, Kim J,
Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, et al: Predictive and
prognostic impact of epidermal growth factor receptor mutation in
non-small-cell lung cancer patients treated with gefitinib. J Clin
Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takano T, Ohe Y, Sakamoto H, Tsuta K,
Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine
I, et al: Epidermal growth factor receptor gene mutations and
increased copy numbers predict gefitinib sensitivity in patients
with recurrent non-small-cell lung cancer. J Clin Oncol.
23:6829–6837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eberhard DA, Johnson BE, Amler LC, Goddard
AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson
DH, et al: Mutations in the epidermal growth factor receptor and in
KRAS are predictive and prognostic indicators in patients with
non-small-cell lung cancer treated with chemotherapy alone and in
combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jänne PA, Borras AM, Kuang Y, Rogers AM,
Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, et
al: A rapid and sensitive enzymatic method for epidermal growth
factor receptor mutation screening. Clin Cancer Res. 12:751–758.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ichihara S, Toyooka S, Fujiwara Y, Hotta
K, Shigematsu H, Tokumo M, Soh J, Asano H, Ichimura K, Aoe K, et
al: The impact of epidermal growth factor receptor gene status on
gefitinib-treated Japanese patients with non-small-cell lung
cancer. Int J Cancer. 120:1239–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pallis AG, Voutsina A, Kalikaki A,
Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M,
Stathopoulos E, Mavroudis D, et al: ‘Classical’ but not ‘other’
mutations of EGFR kinase domain are associated with clinical
outcome in gefitinib-treated patients with non-small cell lung
cancer. Br J Cancer. 97:1560–1566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sequist LV, Martins RG, Spigel D, Grunberg
SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky
A, et al: First-line gefitinib in patients with advanced
non-small-cell lung cancer harboring somatic EGFR mutations. J Clin
Oncol. 26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH,
Hsu YC, Shih JY, Lee YC and Yang PC: Frequent epidermal growth
factor receptor gene mutations in malignant pleural effusion of
lung adenocarcinoma. Eur Respir J. 32:924–930. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
‘uncommon’ epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Pas T, Toffalorio F, Manzotti M,
Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M,
Spaggiari L, De Braud F, et al: Activity of epidermal growth factor
receptor-tyrosine kinase inhibitors in patients with non-small cell
lung cancer harboring rare epidermal growth factor receptor
mutations. J Thorac Oncol. 6:1895–1901. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takahashi R, Hirata H, Tachibana I,
Shimosegawa E, Inoue A, Nagatomo I, Takeda Y, Kida H, Goya S,
Kijima T, et al: Early [18F]fluorodeoxyglucose positron emission
tomography at two days of gefitinib treatment predicts clinical
outcome in patients with adenocarcinoma of the lung. Clin Cancer
Res. 18:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee JK, Shin JY, Kim S, Lee S, Park C, Kim
JY, Koh Y, Keam B, Min HS, Kim TM, et al: Primary resistance to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) in patients with non-small-cell lung cancer harboring
TKI-sensitive EGFR mutations: An exploratory study. Ann Oncol.
24:2080–2087. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Umekawa K, Kimura T, Kudoh S, Suzumura T,
Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, et
al: Plasma RANTES IL-10, and IL-8 levels in non-small-cell lung
cancer patients treated with EGFR-TKIs. BMC Res Notes. 6:1392013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Locatelli-Sanchez M, Couraud S, Arpin D,
Riou R, Bringuier PP and Souquet PJ: Routine EGFR molecular
analysis in non-small-cell lung cancer patients is feasible: Exons
18–21 sequencing results of 753 patients and subsequent clinical
outcomes. Lung. 191:491–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Keam B, Kim DW, Park JH, Lee JO, Kim TM,
Lee SH, Chung DH and Heo DS: Rare and complex mutations of
epidermal growth factor receptor, and efficacy of tyrosine kinase
inhibitor in patients with non-small cell lung cancer. Int J Clin
Oncol. 19:594–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guan Y, Zhao H, Meng J, Yan X and Jiao S:
Dramatic response to high-dose icotinib in a lung adenocarcinoma
patient after erlotinib failure. Lung Cancer. 83:305–307. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watanabe S, Minegishi Y, Yoshizawa H,
Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma
A, et al: Effectiveness of gefitinib against non-small-cell lung
cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac
Oncol. 9:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fukihara J, Watanabe N, Taniguchi H,
Kondoh Y, Kimura T, Kataoka K, Matsuda T, Yokoyama T and Hasegawa
Y: Clinical predictors of response to EGFR tyrosine kinase
inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Oncology. 86:86–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chiu CH, Yang CT, Shih JY, Huang MS, Su
WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, et al: Epidermal
growth factor receptor tyrosine kinase inhibitor treatment response
in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations.
J Thorac Oncol. 10:793–799. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu J, Jin B, Chu T, Dong X, Yang H, Zhang
Y, Wu D, Lou Y, Zhang X, Wang H, et al: EGFR tyrosine kinase
inhibitor (TKI) in patients with advanced non-small cell lung
cancer (NSCLC) harboring uncommon EGFR mutations: A real-world
study in China. Lung Cancer. 96:87–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mitsudomi T, Kosaka T and Yatabe Y:
Biological and clinical implications of EGFR mutations in lung
cancer. Int J Clin Oncol. 11:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mitsudomi T and Yatabe Y: Mutations of the
epidermal growth factor receptor gene and related genes as
determinants of epidermal growth factor receptor tyrosine kinase
inhibitors sensitivity in lung cancer. Cancer Sci. 98:1817–1824.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Klughammer B, Brugger W, Cappuzzo F,
Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin
AY, et al: Examining treatment outcomes with erlotinib in patients
with advanced non-small cell lung cancer whose tumors harbor
uncommon EGFR mutations. J Thorac Oncol. 11:545–555. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Arrieta O, Cardona AF, Corrales L,
Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J,
Vargas C, Carranza H, Otero J, et al: CLICaP: The impact of common
and rare EGFR mutations in response to EGFR tyrosine kinase
inhibitors and platinum-based chemotherapy in patients with
non-small cell lung cancer. Lung Cancer. 87:169–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Oda K, Matsuoka Y, Funahashi A and Kitano
H: A comprehensive pathway map of epidermal growth factor receptor
signaling. Mol Syst Biol. 1:2005.00102005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Choi SH, Mendrola JM and Lemmon MA:
EGF-independent activation of cell-surface EGF receptors harboring
mutations found in gefitinib-sensitive lung cancer. Oncogene.
26:1567–1576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Greulich H, Chen TH, Feng W, Jänne PA,
Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR,
et al: Oncogenic transformation by inhibitor-sensitive and
-resistant EGFR mutants. PLoS Med. 2:e3132005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen Y-R, Fu Y-N, Lin C-H, Yang ST, Hu SF,
Chen YT, Tsai SF and Huang SF: Distinctive activation patterns in
constitutively active and gefitinib-sensitive EGFR mutants.
Oncogene. 25:1205–1215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jiang J, Greulich H, Jänne PA, Sellers WR,
Meyerson M and Griffin JD: Epidermal growth factor-independent
transformation of Ba/F3 cells with cancer-derived epidermal growth
factor receptor mutants induces gefitinib-sensitive cell cycle
progression. Cancer Res. 65:8968–8974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kancha RK, von Bubnoff N, Peschel C and
Duyster J: Functional analysis of epidermal growth factor receptor
(EGFR) mutations and potential implications for EGFR targeted
therapy. Clin Cancer Res. 15:460–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kancha RK, Peschel C and Duyster J: The
epidermal growth factor receptor-L861Q mutation increases kinase
activity without leading to enhanced sensitivity toward epidermal
growth factor receptor kinase inhibitors. J Thorac Oncol.
6:387–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Furuyama K, Harada T, Iwama E, Shiraishi
Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, et al:
Sensitivity and kinase activity of epidermal growth factor receptor
(EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Cancer Sci. 104:584–589. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu
F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK, et al:
Pharmacology and signaling properties of epidermal growth factor
receptor isoforms studied by bioluminescence resonance energy
transfer. Mol Pharmacol. 71:508–518. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yoshikawa S, Kukimoto-Niino M, Parker L,
Handa N, Terada T, Fujimoto T, Terazawa Y, Wakiyama M, Sato M, Sano
S, et al: Structural basis for the altered drug sensitivities of
non-small cell lung cancer-associated mutants of human epidermal
growth factor receptor. Oncogene. 32:27–38. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yun CH, Boggon TJ, Li Y, Woo MS, Greulich
H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR
mutants and inhibitor complexes: Mechanism of activation and
insights into differential inhibitor sensitivity. Cancer Cell.
11:217–227. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shtiegman K, Kochupurakkal BS, Zwang Y,
Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y,
et al: Defective ubiquitinylation of EGFR mutants of lung cancer
confers prolonged signaling. Oncogene. 26:6968–6978. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Doss GP, Rajith B, Chakraborty C,
NagaSundaram N, Ali SK and Zhu H: Structural signature of the
G719S-T790M double mutation in the EGFR kinase domain and its
response to inhibitors. Sci Rep. 4:58682014.PubMed/NCBI
|
|
63
|
Yuza Y, Glatt KA, Jiang J, Greulich H,
Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, et al:
Allele-dependent variation in the relative cellular potency of
distinct EGFR inhibitors. Cancer Biol Ther. 6:661–667. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tracy S, Mukohara T, Hansen M, Meyerson M,
Johnson BE and Jänne PA: Gefitinib induces apoptosis in the
EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res.
64:7241–7244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Helfrich BA, Raben D, Varella-Garcia M,
Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin
WA, et al: Antitumor activity of the epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839,
Iressa) in non-small cell lung cancer cell lines correlates with
gene copy number and EGFR mutations but not EGFR protein levels.
Clin Cancer Res. 12:7117–7125. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sharma SV, Gajowniczek P, Way IP, Lee DY,
Jiang J, Yuza Y, Classon M, Haber DA and Settleman J: A common
signaling cascade may underlie ‘addiction’ to the Src, BCR-ABL, and
EGF receptor oncogenes. Cancer Cell. 10:425–435. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Malaney P, Nicosia SV and Davé V: One
mouse, one patient paradigm: New avatars of personalized cancer
therapy. Cancer Lett. 344:1–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gazdar AF, Hirsch FR and Minna JD: From
mice to men and back: An assessment of preclinical model systems
for the study of lung cancers. J Thorac Oncol. 11:287–299. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
National Comprehensive Cancer Network, .
Clinical Practice Guidelines in Oncology (NCCN
Guidelines®): Non-Small Cell Lung Cancer (Version 4.
2016). 2016 https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfJuly
5–2016.
|
|
72
|
Sebastian M, Schmittel A and Reck M:
First-line treatment of EGFR-mutated nonsmall cell lung cancer:
Critical review on study methodology. Eur Respir Rev. 23:92–105.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Subramaniam D, He AR, Hwang J, Deeken J,
Pishvaian M, Hartley ML and Marshall JL: Irreversible multitargeted
ErbB family inhibitors for therapy of lung and breast cancer. Curr
Cancer Drug Targets. 14:775–793. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Stasi I and Cappuzzo F: Second generation
tyrosine kinase inhibitors for the treatment of metastatic
non-small-cell lung cancer. Transl Respir Med. 2:22014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cross DAE, Ashton SE, Ghiorghiu S,
Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA,
Mellor MJ, et al: AZD9291, an irreversible EGFR TKI overcomes T
790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer
Discov. 4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sequist LV, Besse B, Lynch TJ, Miller VA,
Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, et
al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase
inhibitor: Results of a phase II trial in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 28:3076–3083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yang JC, Sequist LV, Geater SL, Tsai CM,
Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, et al:
Clinical activity of afatinib in patients with advanced
non-small-cell lung cancer harbouring uncommon EGFR mutations: A
combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung
6. Lancet Oncol. 16:830–838. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Mitsudomi T, Kosaka T, Endoh H, Horio Y,
Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small-cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Baek JH, Sun JM, Min YJ, Cho EK, Cho BC,
Kim JH, Ahn MJ and Park K: Efficacy of EGFR tyrosine kinase
inhibitors in patients with EGFR-mutated non-small cell lung cancer
except both exon 19 deletion and exon 21 L858R: A retrospective
analysis in Korea. Lung Cancer. 87:148–154. 2015. View Article : Google Scholar : PubMed/NCBI
|
